Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease

Parkinson Disease Clinical Trial

Official title:

Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05482126
• Other study ID #: IRB-300008936
• Secondary ID: R01NS124563
• Status: Recruiting
• Start date: June 8, 2022
• Est. completion date: September 30, 2026

Study information

• Verified date: April 2024
• Source: University of Alabama at Birmingham
• Contact: Zachary Irwin, PhD
• Phone: (205) 934-6704
• Email: zirwin[@]uabmc.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators are investigating the brain activity associated with sensory information in movement disorders in order to improve treatment of these symptoms beyond what is currently available.

Description:

The purpose of this study is to investigate the functional role of the human basal ganglia in the sensorimotor system. In particular, the investigators are interested in the possibility that the basal ganglia participate in "filtering out" sensory stimuli that are irrelevant to the current behavioral goal. Additionally, the investigators are interested in how this type of sensorimotor processing in these brain areas is related to the severity of movement disorders such as Parkinson's disease and essential tremor.

To do this, the investigators will study both healthy individuals and Parkinson's disease patients undergoing routine deep brain stimulation (DBS) surgery. During the surgery, investigators will place the DBS electrode as routinely performed and additionally place an extra, temporary "strip" electrode along the surface of the brain. Participants will then perform a short behavioral task testing sensorimotor function while investigators record the neural signals from these electrodes. The task will involve the delivery of sensory stimuli (visual, vibrotactile, electrical, and/or proprioceptive), to which the participant will be asked to perform a certain motor response. In order to fully measure the variables of interest, investigators will also attach small stickers (electrodes) to the skin of areas involved in movements for measuring muscle activity (such as the face and limbs), and may attach small, noninvasive devices around the wrist, finger, or arm (e.g., accelerometers) that measure position. The investigators may also apply EEG electrodes to the scalp to measure global brain activity or place a microphone in front of the subject to record speech.

In addition to recording this baseline brain activity, the investigators will evaluate whether deep brain stimulation and dopaminergic medication alters the recorded activity and task performance. Typical deep brain stimulation involves administering specific parameters of high-frequency electrical pulses to achieve clinical benefit. Routine operations involve testing these parameters in the OR in awake patients. For this study, investigators will administer either this high-frequency stimulation or various other patterns of stimulation (e.g., low-frequency, burst stimulation) and measure the changes in behavior and brain activity. As a method of validation, the investigators will also deliver paired pulses of stimulation that enable analysis of stimulation-evoked activity.

Finally, the investigators will correlate recorded brain activity with measures of participants' individual disease severity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 30, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 89 Years

Eligibility

Inclusion criteria (PD participants):

1. Age >18 years

2. Clinically definite, advanced idiopathic PD based on consensus criteria.

3. Normal, or essentially normal, preoperative brain MRI.

4. Patient is available for follow-up visits over the length of the study

5. Patient has elected to undergo DBS surgery as part of routine care, and subthalamic nucleus (STN) is determined as the appropriate surgical target

Inclusion criteria (control participants):

1. Age >18 years.

2. No diagnosis of PD, other movement disorder, or other significant neurological disease.

Exclusion criteria (PD participants):

1. Age <18 years.

2. Medical contraindications such as current uncontrolled hypertension, heart disease, coagulopathy, or other conditions that might increase the risk of surgery

3. Diagnosis or suspicion of atypical Parkinsonism (PSP, MSA, CBD) or drug-induced Parkinsonism, or significant neurological disease other than PD.

4. Diagnosis of psychogenic movement disorder based on consensus criteria

5. Prior DBS surgery or ablation

6. Clinical dementia and/or Dementia Rating Scale (DRS) score of <5th percentile adjusted for age and education level, based upon routine pre-op NP testing.

7. Unable to withhold dopaminergic medications for at least 12 hours prior to scheduled visit

Exclusion criteria (control participants):

1. Age <18 years.

2. Previous diagnosis of PD, other movement disorder, or other significant neurological disease.

Related Conditions & MeSH terms

• Ganglion Cysts
• Parkinson Disease

Intervention

Diagnostic Test:
• Intraoperative Behavioral Testing
During DBS surgery, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
• Behavioral Testing
In the lab, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.

Locations

Country	Name	City	State
United States	The University of Alabama at Birmingham Hospital	Birmingham	Alabama

Sponsors (2)

Lead Sponsor	Collaborator
University of Alabama at Birmingham	National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kinematic response to stimulus (intraoperative)	Arm movements (hand position, velocity) recorded following stimulus onset, measured by joystick outputs.	Intraoperative
Primary	Kinematic response to stimulus (postoperative)	Arm movements (hand position, velocity) recorded following stimulus onset, measured by joystick outputs.	1 month post-op
Primary	Latency of response to stimulus (intraoperative)	Time from stimulus onset to start of motor response, measured by electromyography (EMG)	Intraoperative
Primary	Latency of response to stimulus (postoperative)	Time from stimulus onset to start of motor response, measured by electromyography (EMG)	1 month post-op
Primary	Neural response to stimulus	Brain activity recorded following stimulus onset, measured by local field potentials recorded from the electrocorticography (ECoG) and DBS electrodes.	Intraoperative